Acasti Pharma (ACST) News Today C$0.58 +0.01 (+1.75%) (As of 03/27/2023) Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period April 6, 2024 | finance.yahoo.comAcasti Pharma Inc. (ACST)March 14, 2024 | edition.cnn.comAcasti Pharma Inc. Class AFebruary 25, 2024 | msn.comAcasti Pharma (ACST) Price Target Increased by 200.00% to 6.12February 12, 2024 | finance.yahoo.comAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsDecember 25, 2023 | finance.yahoo.comWill Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?November 14, 2023 | investing.comAcasti Pharma (ACST) Earnings Dates & ReportsNovember 11, 2023 | morningstar.comAcasti Pharma Inc Class A ACSTSeptember 26, 2023 | benzinga.comWhy Acasti Pharma (ACST) Stock Is Exploding HigherSeptember 6, 2023 | technews.tmcnet.comAcasti to Participate in the H.C. Wainwright Global Investment ConferenceAugust 11, 2023 | finanznachrichten.deAcasti Pharma, Inc.: Acasti Announces First Quarter 2024 Financial Results and Business HighlightsJune 23, 2023 | finanznachrichten.deAcasti Pharma Inc.: Acasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 23, 2023 | finance.yahoo.comAcasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 22, 2023 | finance.yahoo.comAcasti Announces Appointment of New Scientific Advisory Board MembersJune 20, 2023 | sg.finance.yahoo.comACST - Acasti Pharma Inc.April 7, 2023 | theglobeandmail.comClosing Bell: Acasti Pharma Inc up on Monday (ACST)April 4, 2023 | seekingalpha.comAcasti Pharma announces CEO transitionMarch 16, 2023 | morningstar.comAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange | MorningstarMarch 8, 2023 | finance.yahoo.comAcasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare ConferenceMarch 4, 2023 | finance.yahoo.comWe're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash WiselyMarch 1, 2023 | finance.yahoo.comAcasti Pharma Recognizes Rare Disease DayFebruary 28, 2023 | msn.comHas Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?January 13, 2023 | benzinga.comAcasti Pharma to Present at Sidoti Virtual Investor Conference on January 18November 15, 2022 | seekingalpha.comAcasti Pharma Inc. (ACST) Q2 2023 Earnings Call TranscriptNovember 9, 2022 | it.tmcnet.comAcasti Pharma to Present at Q4 Investor SummitNovember 8, 2022 | tmcnet.comAcasti Pharma to Report Second Quarter 2023 FinancialSeptember 17, 2022 | theglobeandmail.comAcasti Pharma: Top 10 Undervalued Biotechnology Industry Sector Stocks on TSX Venture Exchange (ACST)September 14, 2022 | finance.yahoo.comAcasti Pharma to Participate in the Lytham Partners Fall 2022 Investor ConferenceSeptember 13, 2022 | it.tmcnet.comAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia TelangiectasiaJuly 27, 2022 | finance.yahoo.comAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic NeuralgiaJuly 9, 2022 | finanznachrichten.deStock Day Media: Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day PodcastJuly 7, 2022 | finance.yahoo.comAcasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day PodcastJune 21, 2022 | seekingalpha.comAcasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2022 Results - Earnings Call TranscriptJune 21, 2022 | seekingalpha.comAcasti Pharma reports GAAP EPS of $0.27 for FY2022May 23, 2022 | stockhouse.comAcasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication ProgramMay 12, 2022 | apnews.comAcasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16thMarch 9, 2022 | finance.yahoo.comAcasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16thFebruary 7, 2022 | finance.yahoo.comAcasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference CallDecember 22, 2021 | benzinga.comThinking about buying stock in Naked Brand, Biondvax Pharmaceuticals, eMagin Corp, Red Cat, or Acasti Pharma?November 24, 2021 | finance.yahoo.comAcasti Pharma CEO to Participate in the Benzinga All Access Event on December 2ndNovember 4, 2021 | finance.yahoo.comAcasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference CallOctober 8, 2021 | proactiveinvestors.comAcasti Pharma outlines key benefits of recent Grace Therapeutics acquisitionOctober 6, 2021 | finance.yahoo.comAcasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in JapanSeptember 29, 2021 | benzinga.comAcasti Pharma Announces Initiation Of Pharmacokinetic Bridging Study For GTX-104August 31, 2021 | msn.comWhy Shares of Acasti Pharma Slumped TuesdayAugust 28, 2021 | benzinga.comAcasti Says 8-For-1 Reverse Stock Split Will Be implemented To Help Regain Nasdaq Compliance Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Alex's "Next Magnificent Seven" Stocks (Ad)Today Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it. Watch Alex's "Next Magnificent Seven" presentation now. ACST Media Mentions By Week ACST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACST News Sentiment▼0.000.62▲Average Medical News Sentiment ACST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACST Articles This Week▼00▲ACST Articles Average Week Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Theratechnologies News Today Sernova News Today Covalon Technologies News Today Small Pharma News Today Microbix Biosystems News Today IBEX Technologies News Today Kane Biotech News Today Ceapro News Today Antibe Therapeutics News Today Resverlogix News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:ACST) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.